HK1183693A1 - Methods for treating eye disorders - Google Patents

Methods for treating eye disorders

Info

Publication number
HK1183693A1
HK1183693A1 HK13111114.3A HK13111114A HK1183693A1 HK 1183693 A1 HK1183693 A1 HK 1183693A1 HK 13111114 A HK13111114 A HK 13111114A HK 1183693 A1 HK1183693 A1 HK 1183693A1
Authority
HK
Hong Kong
Prior art keywords
methods
eye disorders
treating eye
treating
disorders
Prior art date
Application number
HK13111114.3A
Other languages
English (en)
Chinese (zh)
Inventor
．法因施泰因
．艾伯特
．梅特
．巴-伊蘭
．斯皮瓦克
．卡林斯基
．斯拉格爾
Original Assignee
夸克製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 夸克製藥公司 filed Critical 夸克製藥公司
Publication of HK1183693A1 publication Critical patent/HK1183693A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK13111114.3A 2008-10-22 2013-09-27 Methods for treating eye disorders HK1183693A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19699508P 2008-10-22 2008-10-22
US19893108P 2008-11-11 2008-11-11
IL2009000179 2009-02-15

Publications (1)

Publication Number Publication Date
HK1183693A1 true HK1183693A1 (en) 2014-01-03

Family

ID=54839547

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13111114.3A HK1183693A1 (en) 2008-10-22 2013-09-27 Methods for treating eye disorders
HK16100198.2A HK1212883A1 (zh) 2008-10-22 2016-01-08 治療眼部疾病的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16100198.2A HK1212883A1 (zh) 2008-10-22 2016-01-08 治療眼部疾病的方法

Country Status (16)

Country Link
US (4) US8765931B2 (fr)
EP (1) EP2350279B1 (fr)
JP (1) JP5592892B2 (fr)
KR (1) KR101672563B1 (fr)
CN (3) CN102449151A (fr)
AU (1) AU2009308380B2 (fr)
CA (2) CA2738957A1 (fr)
DK (1) DK2350279T3 (fr)
EA (1) EA022418B1 (fr)
ES (1) ES2563984T3 (fr)
HK (2) HK1183693A1 (fr)
IL (1) IL212986A (fr)
NZ (1) NZ591391A (fr)
PL (1) PL2350279T3 (fr)
SI (1) SI2350279T1 (fr)
WO (1) WO2010048352A2 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2293800B1 (fr) 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions et procédés pour le traitement de troubles de l'oreille
ES2563984T3 (es) * 2008-10-22 2016-03-17 Quark Pharmaceuticals, Inc. Métodos para el tratamiento de trastornos oculares
CA2744987C (fr) 2008-12-02 2018-01-16 Chiralgen, Ltd. Procede pour la synthese d'acides nucleiques modifies par des atomes de phosphore
CA2767253A1 (fr) 2009-07-06 2011-01-13 Ontorii, Inc. Nouveaux precurseurs d'acide nucleique et leurs methodes d'utilisation
CN102625841A (zh) * 2009-08-11 2012-08-01 欧科库尔纳有限责任公司 通过抑制脂连蛋白(adipoq)的天然反义转录物治疗脂连蛋白(adipoq)相关疾病
TW201124160A (en) 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
WO2012006083A2 (fr) * 2010-07-09 2012-01-12 University Of Florida Research Foundation, Inc. Siarn ciblés à médiation par un récepteur
EP2620428B1 (fr) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
EP3248982A1 (fr) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Reactifs de type thiosulfonate pour la synthèse d'acides nucléiques fonctionnalisés
US9422560B2 (en) * 2011-11-03 2016-08-23 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
EP2776565A1 (fr) * 2011-11-08 2014-09-17 Quark Pharmaceuticals, Inc. Méthodes et compositions destinées à traiter des maladies, des troubles ou une lésion du système nerveux
AU2013206951B2 (en) 2012-01-04 2016-11-24 Quark Pharmaceuticals, Inc. Double-stranded RNA compounds to CASP2 and uses thereof
WO2014010718A1 (fr) 2012-07-13 2014-01-16 株式会社新日本科学 Adjuvant d'acide nucléique chiral
EP4219516A3 (fr) 2012-07-13 2024-01-10 Wave Life Sciences Ltd. Controle chiral
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
US9932578B2 (en) * 2012-09-12 2018-04-03 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to P53 and methods of use thereof
EP2895608B1 (fr) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Molécules d'oligonucléotide à double brin p53 et procédés d'utilisation correspondants
WO2014050301A1 (fr) * 2012-09-27 2014-04-03 千寿製薬株式会社 Médicament liquide aqueux
ES2697249T3 (es) * 2013-03-11 2019-01-22 Fond Telethon miR-204 y miR-211 y usos de los mismos
LT2970974T (lt) * 2013-03-14 2017-12-11 Alnylam Pharmaceuticals, Inc. Komplemento komponento c5 irnr kompozicijos ir jų panaudojimas
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108046A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
RU2016133035A (ru) 2014-01-16 2018-02-21 Уэйв Лайф Сайенсес Лтд. Хиральный дизайн
EP3191591A1 (fr) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Agents polynucléotidiques ciblant le composant du complément c5 et leurs méthodes d'utilisation
EP3334499A4 (fr) 2015-08-14 2019-04-17 University of Massachusetts Conjugués bioactifs pour l'administration d'oligonucléotides
MA44908A (fr) 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
JP7176756B2 (ja) * 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
AU2017322522B2 (en) * 2016-09-09 2024-01-04 Cornell University Delivery of nucleic acids, proteins and small molecules in vitreous vesicular bodies
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
KR20190077471A (ko) * 2016-11-02 2019-07-03 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 방향 선택적인 망막 신경절 세포에서의 유전자의 특이적 발현을 위한 프로모터, synp198
RU2633349C1 (ru) * 2016-11-24 2017-10-11 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ определения дифференцированных показаний к срокам лечения нарушений прекорнеальной слезной пленки после лазерного in situ кератомилеза с фемтолазерным сопровождением у детей
CA3043768A1 (fr) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes destines a l'administration d'agents therapeutiques
RU2643579C1 (ru) * 2017-03-29 2018-02-02 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемической нейропатии зрительного нерва карбамилированным дарбэпоэтином в эксперименте
US10844377B2 (en) 2017-06-23 2020-11-24 University Of Massachusetts Two-tailed self-delivering siRNA
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
CN110604811B (zh) * 2018-06-14 2023-01-31 陕西慧康生物科技有限责任公司 含有重组人溶菌酶和重组人表皮生长因子的人工泪液
CA3103740A1 (fr) 2018-06-29 2020-01-02 Wuhan Neurophth Biotechnology Limited Company Compositions et methodes de traitement de la neuropathie optique hereditaire de leber
CA3109432A1 (fr) * 2018-08-20 2020-02-27 Wuhan Neurophth Biotechnology Limited Company Compositions et methodes de traitement de la neuropathie optique hereditaire de leber
JP7520851B2 (ja) 2018-09-21 2024-07-23 アウフバウ・メディカル・イノベイションズ・リミテッド 緑内障用の組成物および方法
US20220093005A1 (en) * 2019-01-22 2022-03-24 The Board Of Trustees Of The Leland Stanford Junior University Silicone Oil-Induced Ocular Hypertension Glaucoma Model
MX2022001710A (es) 2019-08-09 2022-05-10 Univ Massachusetts Oligonucleótidos modificados químicamente dirigidos a los snp.
US11969451B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
BR102020023560A8 (pt) * 2019-11-19 2023-02-07 Johnson & Johnson Consumer Inc Composições e métodos para tratar os olhos
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
CN112063624A (zh) * 2020-09-19 2020-12-11 湖南中医药大学 一种抑制caspase 1基因表达的siRNA分子及其应用
AU2022261359A1 (en) 2021-04-19 2023-10-12 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression
WO2023014654A2 (fr) * 2021-08-02 2023-02-09 University Of Massachusetts Oligonucléotides pour modulation de htt-1a
AU2022378567A1 (en) 2021-10-29 2024-04-11 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251666B1 (en) * 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
AU2001289068A1 (en) * 2000-09-20 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 2 expression
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
CA2465860A1 (fr) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Procedes et compositions permettant l'utilisation therapeutique de l'interference arn
ES2280826T5 (es) * 2002-08-05 2017-08-03 Silence Therapeutics Gmbh Nuevas formas adicionales de moléculas de ARN de interferencia
JP2006520611A (ja) * 2003-03-05 2006-09-14 セネスコ テクノロジーズ，インコーポレイティド ｅＩＦ−５Ａ１の発現を抑制するための、アンチセンス・オリゴヌクレオチド又はｓｉＲＮＡの使用
FR2855054B1 (fr) * 2003-05-22 2005-07-08 Theraptosis Moyens pour bloquer ou retarder une mort cellulaire in vitro
CA2526493A1 (fr) * 2003-05-22 2004-12-02 Theraptosis S.A. Moyens pour prevenir et traiter la mort cellulaire et applications biologiques associees
AP2007003921A0 (en) 2004-08-16 2007-02-28 Atugen Ag Therapeutic uses of inhibitors of rtp801
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
WO2008104978A2 (fr) 2007-02-28 2008-09-04 Quark Pharmaceuticals, Inc. Nouvelles structures d'arnsi
CN103898110A (zh) * 2007-10-03 2014-07-02 夸克制药公司 新siRNA结构
ES2563984T3 (es) * 2008-10-22 2016-03-17 Quark Pharmaceuticals, Inc. Métodos para el tratamiento de trastornos oculares

Also Published As

Publication number Publication date
CA2738957A1 (fr) 2010-04-29
CA2962219C (fr) 2020-08-25
AU2009308380B2 (en) 2015-05-28
CA2962219A1 (fr) 2010-04-29
AU2009308380A1 (en) 2010-04-29
JP5592892B2 (ja) 2014-09-17
CN102449151A (zh) 2012-05-09
EA022418B1 (ru) 2015-12-30
DK2350279T3 (en) 2016-02-15
CN102994500A (zh) 2013-03-27
ES2563984T3 (es) 2016-03-17
US20170306329A1 (en) 2017-10-26
IL212986A0 (en) 2011-07-31
CN102994500B (zh) 2015-04-01
IL212986A (en) 2016-05-31
WO2010048352A8 (fr) 2011-08-11
EP2350279B1 (fr) 2016-01-27
US20150050328A1 (en) 2015-02-19
HK1212883A1 (zh) 2016-06-24
US20150361430A1 (en) 2015-12-17
KR20110081826A (ko) 2011-07-14
SI2350279T1 (sl) 2016-04-29
KR101672563B1 (ko) 2016-11-03
JP2012506450A (ja) 2012-03-15
WO2010048352A2 (fr) 2010-04-29
NZ591391A (en) 2012-10-26
PL2350279T3 (pl) 2016-05-31
US9701961B2 (en) 2017-07-11
WO2010048352A3 (fr) 2010-06-17
US9121020B2 (en) 2015-09-01
CN104857526A (zh) 2015-08-26
US8765931B2 (en) 2014-07-01
EA201170551A1 (ru) 2011-12-30
CN104857526B (zh) 2019-03-05
EP2350279A2 (fr) 2011-08-03
US20110229557A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
HK1212883A1 (zh) 治療眼部疾病的方法
IL257418A (en) Methods for treating addiction
WO2010144865A9 (fr) Procédés de traitement de troubles gastro-intestinaux
EP2083857A4 (fr) Procédés pour traiter des troubles en rapport avec le mica
GB2467710B (en) Methods for treating social disorders
EP2331088A4 (fr) Compositions et procédés de traitement de troubles psychiatriques
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
IL212348A0 (en) Treatment method
EP2323681A4 (fr) Procédés de traitement d'affections virales
PL2635299T3 (pl) Sposoby leczenia zaburzeń utraty włosów
EP2365747A4 (fr) Procédés de traitement de maladies gastro-intestinales
EP2307035A4 (fr) Traitement de l'épilepsie
HK1203516A1 (en) Methods for treating psoriasis
EP2341936A4 (fr) PROCÉDÉS POUR LE TRAITEMENT OU LA PRÉVENTION DES MALADIES ASSOCIÉES À IL-1ß
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2331097A4 (fr) Procédés de traitement de troubles du système nerveux central (cns)
EP2477635A4 (fr) Méthodes de traitement de tumeurs cérébrales
EP2296682B8 (fr) Procédés de traitement de troubles ophtalmiques
ZA201009226B (en) Nifurtimox for treating disease caused by trichomonadida
SG175106A1 (en) Method for treating immune disorders
EP2249837A4 (fr) Méthodes de traitement de troubles thromboemboliques
EP2387402A4 (fr) Procédés pour le traitement de troubles inflammatoires au moyen de composés de la 2,4-pyrimidine diamine
EP2296461A4 (fr) Procédés de traitement d'arthropodes
IL207906A0 (en) Treatment for ocular-related disorders
EP2496080A4 (fr) Méthode de traitement de la maladie de parkinson